enGene Holdings Inc.

NASDAQ:ENGN

Biotechnology

Healthcare
$1.85 -1.15%

-$0.02 today

Market cap
$123.98M
Beta
-0.29
P/E (TTM)
-1.8
EPS (TTM)
-$0.95
52W Low $1.40High $12.25

Volume 2.81M

Average 1.58M

ENGN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

enGene Holdings Inc.NASDAQ: ENGN

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Apr 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 69.72M shares rose 36.7% year over year, ahead of the +25.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at +47.9% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +36.7% holds above the trailing-twelve-month pace of +25.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
69.72M+3.7% QoQ
Last fiscal yearOct 2025
51.12M+14.5% YoY
LTMApr 2026
59.85M+25.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+36.7%——
1 year+14.5%——
3-year CAGR+47.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
51.12M USD
Year-over-year change
+14.5%
4-year CAGR
+34.1%

Weighted Avg Shares (Diluted) vs competitors

How ENGN compares with its peers on the latest reported figures

  • ENGN's LTM Apr 2026 weighted avg shares (diluted) of 59.85M shares is the 7th highest of the 11 companies compared; the peer median is 83.42M shares.
  • Its year-over-year change of +25.2% is the 2nd highest of 10, against a peer median of +8.7%.
  • Over three fiscal years its annual growth of +47.9% compares with a peer median of +26.7%.
ENGN Competitors Peer median
Weighted Avg Shares (Diluted) for ENGN and competitors
Company Period LTM YoY 3-year CAGR
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
ACIUAC Immune S.A.LTM Mar 202699.9M -0.5%+6.4%
ALTAltimmune, Inc.LTM Mar 202698.99M +37.1%+23.4%
DBVTDBV Technologies S.A.LTM Mar 202688.66M -7.8%+3.7%
LRMRLarimar Therapeutics, Inc.LTM Mar 202678.18M +22.5%+41.5%
ENGNenGene Holdings Inc.LTM Apr 202659.85M +25.2%+47.9%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
AMRNAmarin Corporation plcLTM Mar 202620.78M +1.0%+1.1%
KRROKorro Bio, Inc.LTM Mar 20269.94M +8.7%+232.7%
Peer median (excluding ENGN) 83.42M+8.7%+26.7%

Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development12.46M15.47M16.46M38.32M94.48M
Selling, General & Admin3.16M3.26M8.47M23.98M28.69M
Operating Expenses15.87M19.43M26.06M62.3M123.17M
Depreciation & Amortization272K238K175K323K509K
EBITDA(18.15M)(22.78M)(94.77M)(52.04M)(113.8M)
EBITDA Margin—————
Operating Income(15.87M)(19.43M)(26.06M)(62.3M)(123.17M)
Operating Margin—————
Interest Income25K129K1.12M10.41M9.43M
Interest Expense5.02M1.42M4.95M2.8M2.99M
Other Income / Expenses(7.57M)(5.01M)(73.84M)7.14M5.86M
Income Before Tax(23.44M)(24.44M)(99.9M)(55.16M)(117.3M)
Pre-Tax Margin—————
Income Tax Expense022K17K(19K)0
Net Income(23.44M)(24.46M)(99.92M)(55.14M)(117.3M)
Net Margin—————
EPS (Basic)(0.01)0.00(4.24)(1.46)(2.29)
EPS (Diluted)(0.01)0.00(4.24)(1.46)(2.29)
Weighted Avg Shares15.81M15.81M23.56M44.64M51.12M
Weighted Avg Shares (Diluted)15.81M15.81M23.56M44.64M51.12M

enGene Holdings Inc.

NASDAQ:ENGN

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.